Ascendis Pharma A/S (ASND) Most Active Options
The 22 most actively traded Ascendis Pharma A/S (ASND) option contracts at the latest daily snapshot, ranked by volume. Each row shows the contract's price, implied volatility, delta, open interest, and how today's volume compares with its own 30-day average — click a contract to analyze it in the OptiView platform.
Data as of Aug 24, 2026, 3:55 PM ET · OPRA data 15 minutes delayed · For information only — not investment advice.
Most Active ASND Contracts
| Contract | Expiration | DTE | Last | IV | IV rank (30d) | Delta | Open interest | Volume | vs 30d avg |
|---|---|---|---|---|---|---|---|---|---|
| ASND $350 call | Sep 18, 2026 | 25d | $0.06 | 73.8% | 59 | 0.06 | 1 | 63 | 11.7× avg |
| ASND $270 call | Sep 18, 2026 | 25d | $3.90 | 0.0% | 0 | 1.00 | 124 | 25 | 9.2× avg |
| ASND $250 call | Oct 16, 2026 | 53d | $16.20 | — | — | — | 31 | 20 | — |
| ASND $160 call | Sep 18, 2026 | 25d | $92.50 | 66.0% | 37 | 1.00 | 3 | 10 | 86.7× avg |
| ASND $150 call | Oct 16, 2026 | 53d | $103.00 | — | — | — | 0 | 9 | — |
| ASND $270 call | Oct 16, 2026 | 53d | $8.50 | — | — | — | 243 | 6 | — |
| ASND $230 put | Sep 18, 2026 | 25d | $2.88 | — | — | — | 8 | 5 | — |
| ASND $200 call | Jan 15, 2027 | 144d | $60.00 | — | — | — | 20 | 3 | — |
| ASND $230 call | Sep 18, 2026 | 25d | $23.84 | 39.2% | 0 | 0.83 | 4 | 3 | 12.0× avg |
| ASND $175 call | Sep 18, 2026 | 25d | $77.40 | 0.0% | 0 | 1.00 | 1 | 3 | 26.0× avg |
| ASND $260 call | Sep 18, 2026 | 25d | $7.00 | 0.0% | 0 | 1.00 | 141 | 3 | 1.1× avg |
| ASND $220 call | Dec 17, 2027 | 480d | $67.98 | — | — | — | 2 | 2 | — |
| ASND $290 call | Sep 18, 2026 | 25d | $1.00 | 44.0% | 26 | 0.13 | 219 | 2 | 0.5× avg |
| ASND $240 call | Oct 16, 2026 | 53d | $20.85 | 0.0% | 0 | 1.00 | 29 | 2 | 5.5× avg |
| ASND $260 call | Oct 16, 2026 | 53d | $12.60 | — | — | — | 8 | 1 | — |
| ASND $165 call | Sep 18, 2026 | 25d | $87.50 | 0.0% | 0 | 1.00 | 3 | 1 | 8.7× avg |
| ASND $290 call | Oct 16, 2026 | 53d | $3.50 | — | — | — | 2 | 1 | — |
| ASND $300 call | Oct 16, 2026 | 53d | $2.50 | — | — | — | 2 | 1 | — |
| ASND $170 call | Sep 18, 2026 | 25d | $82.50 | — | — | — | 2 | 1 | — |
| ASND $300 call | Jan 15, 2027 | 144d | $9.38 | 0.0% | 0 | 1.00 | 10 | 1 | 6.1× avg |
| ASND $300 call | Mar 19, 2027 | 207d | $13.58 | — | — | — | 2 | 1 | — |
| ASND $240 put | Sep 18, 2026 | 25d | $5.00 | 500.0% | 100 | 0.00 | 66 | 1 | 0.8× avg |
Ranked by volume at the latest daily snapshot. "vs 30d avg" compares today's volume with the contract's own 30-day average.
The most active ASND contract today is the $350 call expiring in 25 days, with 63 contracts traded. Calls dominate the most-active list (20 of the top 22), showing where trading interest concentrates.
Explore the payoff profile of option on ASND for free
Build multi-leg ASND strategies, visualize payoffs, and scan the full US options universe with OptiView.
ASND Options FAQ
Which ASND option contract is most active today?
The most traded ASND contract is the $350 call expiring Sep 18, 2026, with 63 contracts traded as of Aug 24, 2026.
How does OptiView rank the most active ASND options?
The table lists the 22 ASND contracts with the highest volume at the latest daily snapshot, alongside price, implied volatility, delta, open interest, and each contract's volume versus its own 30-day average.
Methodology. IV rank compares the current 30-day at-the-money implied volatility with its highest and lowest values over the past 52 weeks. Max pain is the strike that minimizes the total payout to option holders at expiration. The call and put walls are the strikes carrying the largest call and put open interest across all expirations. Net gamma exposure (GEX) is measured from the dealer perspective. All statistics are derived from delayed OPRA options data.
Options trading involves significant risk, and losses can exceed your initial investment. Always consult a licensed financial professional before making investment decisions. OptiView does not provide financial advice; all figures on this page are descriptive statistics, not recommendations.